These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
220 related articles for article (PubMed ID: 7791418)
1. Third-generation cephalosporins. Klein NC; Cunha BA Med Clin North Am; 1995 Jul; 79(4):705-19. PubMed ID: 7791418 [TBL] [Abstract][Full Text] [Related]
3. The selection and use of cephalosporins: a review. Klein NC; Cunha BA Adv Ther; 1995; 12(2):83-101. PubMed ID: 10150326 [TBL] [Abstract][Full Text] [Related]
4. [Review of oral cephalosporins. Basis for a rational choice]. Forti IN Medicina (B Aires); 1994; 54(5 Pt 1):439-58. PubMed ID: 7658980 [TBL] [Abstract][Full Text] [Related]
5. In vitro activity, pharmacokinetics, clinical efficacy, safety and pharmacoeconomics of ceftriaxone compared with third and fourth generation cephalosporins: review. Bijie H; Kulpradist S; Manalaysay M; Soebandrio A J Chemother; 2005 Feb; 17(1):3-24. PubMed ID: 15828439 [TBL] [Abstract][Full Text] [Related]
6. Role of cephalosporins in the treatment of bacterial meningitis in adults. Overview with special emphasis on ceftazidime. Norrby SR Am J Med; 1985 Aug; 79(2A):56-61. PubMed ID: 3895919 [TBL] [Abstract][Full Text] [Related]
7. Third generation cephalosporins. Donowitz GR Infect Dis Clin North Am; 1989 Sep; 3(3):595-612. PubMed ID: 2671141 [TBL] [Abstract][Full Text] [Related]
8. Cefotaxime. A pharmacoeconomic review of its use in the treatment of infections. Plosker GL; Foster RH; Benfield P Pharmacoeconomics; 1998 Jan; 13(1 Pt 1):91-106. PubMed ID: 10175990 [TBL] [Abstract][Full Text] [Related]
9. Ceftizoxime. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use. Richards DM; Heel RC Drugs; 1985 Apr; 29(4):281-329. PubMed ID: 3888599 [TBL] [Abstract][Full Text] [Related]
10. Penetration of newer cephalosporins into cerebrospinal fluid. Cherubin CE; Eng RH; Norrby R; Modai J; Humbert G; Overturf G Rev Infect Dis; 1989; 11(4):526-48. PubMed ID: 2672238 [TBL] [Abstract][Full Text] [Related]
11. Cefepime. Cunha BA; Gill MV Med Clin North Am; 1995 Jul; 79(4):721-32. PubMed ID: 7791419 [TBL] [Abstract][Full Text] [Related]
12. Symposium on antimicrobial therapy. IV. The cephalosporins. Greenfield RA J Okla State Med Assoc; 1993 Jan; 86(1):7-12. PubMed ID: 8426246 [TBL] [Abstract][Full Text] [Related]
13. Ceftazidime review. Yost RL; Ramphal R Drug Intell Clin Pharm; 1985; 19(7-8):509-13. PubMed ID: 3896712 [TBL] [Abstract][Full Text] [Related]
14. Development of bacterial resistance to the third generation cephalosporins and their clinical use. Kolár M; Látal T; Hájek V J Chemother; 1999 Aug; 11(4):260-5. PubMed ID: 10465127 [TBL] [Abstract][Full Text] [Related]
17. Drug utilisation review (DUR) of the third generation cephalosporins. Focus on ceftriaxone, ceftazidime and cefotaxime. Adu A; Armour CL Drugs; 1995 Sep; 50(3):423-39. PubMed ID: 8521766 [TBL] [Abstract][Full Text] [Related]
18. Pathophysiologic basis for the use of third-generation cephalosporins. Neu HC Am J Med; 1990 Apr; 88(4A):3S-11S. PubMed ID: 2183607 [TBL] [Abstract][Full Text] [Related]
19. Empiric therapy of severe infections in adults. Modai J Am J Med; 1990 Apr; 88(4A):12S-17S. PubMed ID: 2183604 [TBL] [Abstract][Full Text] [Related]
20. Influence of third-generation cephalosporin resistance on adult in-hospital mortality from post-neurosurgical bacterial meningitis. Chang CJ; Ye JJ; Yang CC; Huang PY; Chiang PC; Lee MH J Microbiol Immunol Infect; 2010 Aug; 43(4):301-9. PubMed ID: 20688290 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]